This new 970-page comprehensive five-country report from Venture Planning Group is designed to help current suppliers and potential market entrants identify and evaluate the major business opportunities emerging in the European molecular diagnostics market during the next five years. The report explores business and technological trends in major European countries (France, Germany, Italy, Spain, UK); provides 5-year test volume/sales forecasts; estimates shares of leading competitors; compares features of major analyzers; profiles leading market players; and identifies specific product and business opportunities facing instrument and consumable suppliers during the next five years.The $4.5 billion molecular diagnostics market is unquestionably the most rapidly growing segment of the in vitro diagnostics industry. The next five years will witness significant developments in reagent systems and automation, as well as introduction of a wide range of new products that will require innovative marketing approaches. The rate of market penetration into routine clinical laboratories, however, will depend on the introduction of and cost-effective automated systems with amplification methods. In order to successfully capitalize on the opportunities presented by the molecular diagnostics market, many companies are already exploiting new technologies as corporate strategic assets, managed in support of business and marketing strategies. Integrating new technology planning with business and corporate strategies will be one of the most challenging tasks for diagnostics companies during the next five years.
Innovative Molecular Diagnostic Technologies and Emerging MarketsReportLinker.com
This unique seven-country report contains 1,050 pages, 96 tables, and is designed to help current suppliers and potential market entrants identify and evaluate major business opportunities emerging in the molecular diagnostics market during this decade. The report explores business and technological trends in the US, five major European countries, (France, Germany, Italy, Spain, UK) and Japan; provides 5- and 10-year test volume/sales forecasts; estimates shares of leading competitors; compares features of major analyzers; profiles leading market players; and identifies specific product and business opportunities facing instrument and consumable suppliers during the next ten years.The molecular diagnostics market is unquestionably the most rapidly growing segment of the in vitro diagnostics industry. The next ten years will witness significant developments in reagent systems and automation, as well as introduction of a wide range of new products that will require innovative marketing approaches. The rate of market penetration into routine clinical laboratories, however, will depend on the introduction of cost-effective and automated systems with amplification methods. In order to successfully capitalize on the opportunities presented by the molecular diagnostics market, many companies are already exploiting new DNA probe and biochip technologies as corporate strategic assets, managed in support of business and marketing strategies. Integrating new technology planning with business and corporate strategies will be one of the most challenging tasks for diagnostics companies during the next ten years.
Future Horizons in the European Molecular Diagnostics Market--France, Germany...ReportLinker.com
This comprehensive five-country report is designed to help current suppliers and potential market entrants identify and evaluate major business opportunities emerging in the molecular diagnostics market during the next five years. The report explores business and technological trends in major European countries (France, Germany, Italy, Spain, UK); provides 5-year test volume/sales forecasts; estimates shares of leading competitors; compares features of major analyzers; profiles leading market players; and identifies specific product and business opportunities facing instrument and consumable suppliers during the next five years.The $4.5 billion molecular diagnostics market is unquestionably the most rapidly growing segment of the in vitro diagnostics industry. The next five years will witness significant developments in reagent systems and automation, as well as introduction of a wide range of new products that will require innovative marketing approaches. The rate of market penetration into routine clinical laboratories, however, will depend on the introduction of cost-effective and automated systems with amplification methods. In order to successfully capitalize on the opportunities presented by the molecular diagnostics market, many companies are already exploiting new technologies as corporate strategic assets, managed in support of business and marketing strategies. Integrating new technology planning with business and corporate strategies will be one of the most challenging tasks for diagnostics companies during the next five years. Contains 970 pages and 75 tables
This report presents a comprehensive analysis of the US blood banking market, including:Major issues pertaining to the US blood banking practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next ten years. Specifically, the study explores the impact of anticipated changes in government regulations, trends in complicated surgeries, birth rate and other key issues.Ten-year volume and sales forecasts for 40 blood typing, grouping and infectious disease screening tests, including NAT procedures performed in US community and regional blood centers, hospitals, commercial laboratories, and plasma fractionation facilities.Annual placements and installed base estimates for major automated and semiautomated analyzers. Review of current instrumentation technologies, and a feature comparison of over 20 analyzers. Ten-year reagent and instrument sales forecasts.Sales and market shares of leading reagent and instrument suppliers.Review of current and emerging technologies, and their potential market applications.Product development opportunities for instruments ,consumables, and auxiliary products.Profiles of major current and emerging suppliers, including their sales, market shares, product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements, and business strategies.Business opportunities and strategic recommendations for suppliers.Contains 460 pages and 53 tables
Innovative Clinical Chemistry and Immunodiagnostic Technologies and Emerging ...ReportLinker.com
This unique 1,115-page report contains 450 tables, and provides sales and market shares of leading reagent and instrument suppliers, as well as test volume and sales forecasts for 100 chemistry, TDM, endocrine, cancer, immunoprotein and abused drug assays, calibrators and controls. Available by country and section.This unique worldwide market intelligence and technology assessment report will help current suppliers and potential market entrants identify and evaluate emerging opportunities and develop effective strategic responses. The report explores future trends in the U.S., five major European countries (France, Germany, Italy, Spain, UK) and Japan; provides estimates of the specimen, test and sales volumes, as well as major suppliers’ sales and market shares; compares features of leading analyzers; profiles key competitors; and identifies specific product and marketing opportunities emerging during the next ten years.The clinical chemistry and immunodiagnostics markets are undergoing significant transformation, caused by convergence of new and more stringent regulations; advances in diagnostic technologies, system engineering, automation, and IT; and intensifying competition. Some segments, like routine chemistry, begin to resemble commodity markets, where product positioning and cost per test are more critical than underlying technology. This evolving marketplace creates exciting opportunities for a variety of new instruments, reagent systems, and auxiliary products, such as specimen preparation devices, controls, and calibrators.
The 2011 Clinical Chemistry and Immunodiagnostics Markets: US, Europe, Japan&...ReportLinker.com
During the next decade, the clinical chemistry and immunodiagnostics markets will undergo significant transformation. The changes will be caused convergence of new and more stringent regulations; advances in diagnostic technologies, system engineering, automation, and IT; and intensifying competition. Some segments, like routine chemistry, will resemble commodity markets, where product positioning and cost per test are more critical than underlying technology. This evolving marketplace will create exciting opportunities for a variety of new instruments, reagent systems, and auxiliary products, such as specimen preparation devices, controls, calibrators and others."The Clinical Chemistry and Immunodiagnostics Markets" is a unique worldwide market intelligence and technology assessment study designed to help current suppliers and potential market entrants identify and evaluate emerging opportunities and develop effective strategic responses. The study explores future trends in the U.S., five major European countries and Japan; provides estimates of the specimen, test and sales volumes, as well as major suppliers' sales and market shares; compares features of leading analyzers; profiles key competitors; and identifies specific product and marketing opportunities facing suppliers during the next ten years.Contains 1,115 pages and 450 tables
European Infectious Disease Testing Market: Innovative Technologies and Emerg...ReportLinker.com
This unique report contains 1,600 pages, 580 tables and provides information not available from any other published source, including volume, sales, and leading supplier shares by test.This comprehensive European survey is designed to assist diagnostics industry executives, as well as companies planning to diversify into the dynamic and rapidly expanding infectious disease testing market, in evaluating emerging opportunities and developing effective business strategies. The report provides market segmentation analysis of over 70 diseases and viruses in five countries, assessment of emerging technologies, review of current instrumentation, as well as strategic profiles of leading suppliers and recent market entrants with innovative technologies and products. The infectious disease testing market is one of the most rapidly growing segments of the in vitro diagnostics industry, and the greatest challenge facing suppliers in the 21st century. Among the main driving forces behind the growth of this dynamic market is continuous spread of AIDS, which remains the world’s major health threat and a major factor contributing to the rise in incidence of opportunistic infections; bioterrorism; advances in molecular diagnostic technologies; and a wider availability of immunosuppressive drugs.Although for some infections the etiology is still a mystery, while for others the causative microorganisms are present in minute concentrations long before the occurrence of first clinical symptoms, recent advances in genetic engineering and detection technologies are creating exciting opportunities for highly sensitive, specific and cost-effective products.Contains 1,600 pages and 580 tables
Future Clinical Chemistry and Immunodiagnostics Markets: Growth Opportunities...ReportLinker.com
During the next decade, the clinical chemistry and immunodiagnostics markets will undergo significant transformation. The changes will be caused convergence of new and more stringent regulations; advances in diagnostic technologies, system engineering, automation, and IT; and intensifying competition. Some segments, like routine chemistry, will resemble commodity markets, where product positioning and cost per test are more critical than underlying technology. This evolving marketplace will create exciting opportunities for a variety of new instruments, reagent systems, and auxiliary products, such as specimen preparation devices, controls, calibrators and others."The Clinical Chemistry and Immunodiagnostics Markets" is a unique worldwide market intelligence and technology assessment study designed to help current suppliers and potential market entrants identify and evaluate emerging opportunities and develop effective strategic responses. The study explores future trends in the U.S., five major European countries and Japan; provides estimates of the specimen, test and sales volumes, as well as major suppliers' sales and market shares; compares features of leading analyzers; profiles key competitors; and identifies specific product and marketing opportunities facing suppliers during the next ten years.Contains 1,115 pages and 450 tables
The 2012 European Clinical Chemistry and Immunodiagnostics Markets:<br>Fra...ReportLinker.com
This unique report provides information not available from any other published source, including volume, sales, and leading supplier shares by test.This market intelligence and technology assessment report will help current suppliers and potential market entrants identify and evaluate emerging opportunities and develop effective strategic responses. The report explores future trends in five major European countries (France, Germany, Italy, Spain, UK) and Japan; provides estimates of the specimen, test and sales volumes, as well as major suppliers’ sales and market shares; compares features of leading analyzers; profiles key competitors; and identifies specific product and marketing opportunities emerging during the next five years.The clinical chemistry and immunodiagnostics markets are undergoing significant transformation, caused by convergence of new and more stringent regulations; advances in diagnostic technologies, system engineering, automation, and IT; and intensifying competition. Some segments, like routine chemistry, begin to resemble commodity markets, where product positioning and cost per test are more critical than underlying technology. This evolving marketplace creates exciting opportunities for a variety of new instruments, reagent systems, and auxiliary products, such as specimen preparation devices, controls, and calibrators.Contains 900 pages and 335 tables
Innovative Molecular Diagnostic Technologies and Emerging MarketsReportLinker.com
This unique seven-country report contains 1,050 pages, 96 tables, and is designed to help current suppliers and potential market entrants identify and evaluate major business opportunities emerging in the molecular diagnostics market during this decade. The report explores business and technological trends in the US, five major European countries, (France, Germany, Italy, Spain, UK) and Japan; provides 5- and 10-year test volume/sales forecasts; estimates shares of leading competitors; compares features of major analyzers; profiles leading market players; and identifies specific product and business opportunities facing instrument and consumable suppliers during the next ten years.The molecular diagnostics market is unquestionably the most rapidly growing segment of the in vitro diagnostics industry. The next ten years will witness significant developments in reagent systems and automation, as well as introduction of a wide range of new products that will require innovative marketing approaches. The rate of market penetration into routine clinical laboratories, however, will depend on the introduction of cost-effective and automated systems with amplification methods. In order to successfully capitalize on the opportunities presented by the molecular diagnostics market, many companies are already exploiting new DNA probe and biochip technologies as corporate strategic assets, managed in support of business and marketing strategies. Integrating new technology planning with business and corporate strategies will be one of the most challenging tasks for diagnostics companies during the next ten years.
Future Horizons in the European Molecular Diagnostics Market--France, Germany...ReportLinker.com
This comprehensive five-country report is designed to help current suppliers and potential market entrants identify and evaluate major business opportunities emerging in the molecular diagnostics market during the next five years. The report explores business and technological trends in major European countries (France, Germany, Italy, Spain, UK); provides 5-year test volume/sales forecasts; estimates shares of leading competitors; compares features of major analyzers; profiles leading market players; and identifies specific product and business opportunities facing instrument and consumable suppliers during the next five years.The $4.5 billion molecular diagnostics market is unquestionably the most rapidly growing segment of the in vitro diagnostics industry. The next five years will witness significant developments in reagent systems and automation, as well as introduction of a wide range of new products that will require innovative marketing approaches. The rate of market penetration into routine clinical laboratories, however, will depend on the introduction of cost-effective and automated systems with amplification methods. In order to successfully capitalize on the opportunities presented by the molecular diagnostics market, many companies are already exploiting new technologies as corporate strategic assets, managed in support of business and marketing strategies. Integrating new technology planning with business and corporate strategies will be one of the most challenging tasks for diagnostics companies during the next five years. Contains 970 pages and 75 tables
This report presents a comprehensive analysis of the US blood banking market, including:Major issues pertaining to the US blood banking practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next ten years. Specifically, the study explores the impact of anticipated changes in government regulations, trends in complicated surgeries, birth rate and other key issues.Ten-year volume and sales forecasts for 40 blood typing, grouping and infectious disease screening tests, including NAT procedures performed in US community and regional blood centers, hospitals, commercial laboratories, and plasma fractionation facilities.Annual placements and installed base estimates for major automated and semiautomated analyzers. Review of current instrumentation technologies, and a feature comparison of over 20 analyzers. Ten-year reagent and instrument sales forecasts.Sales and market shares of leading reagent and instrument suppliers.Review of current and emerging technologies, and their potential market applications.Product development opportunities for instruments ,consumables, and auxiliary products.Profiles of major current and emerging suppliers, including their sales, market shares, product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements, and business strategies.Business opportunities and strategic recommendations for suppliers.Contains 460 pages and 53 tables
Innovative Clinical Chemistry and Immunodiagnostic Technologies and Emerging ...ReportLinker.com
This unique 1,115-page report contains 450 tables, and provides sales and market shares of leading reagent and instrument suppliers, as well as test volume and sales forecasts for 100 chemistry, TDM, endocrine, cancer, immunoprotein and abused drug assays, calibrators and controls. Available by country and section.This unique worldwide market intelligence and technology assessment report will help current suppliers and potential market entrants identify and evaluate emerging opportunities and develop effective strategic responses. The report explores future trends in the U.S., five major European countries (France, Germany, Italy, Spain, UK) and Japan; provides estimates of the specimen, test and sales volumes, as well as major suppliers’ sales and market shares; compares features of leading analyzers; profiles key competitors; and identifies specific product and marketing opportunities emerging during the next ten years.The clinical chemistry and immunodiagnostics markets are undergoing significant transformation, caused by convergence of new and more stringent regulations; advances in diagnostic technologies, system engineering, automation, and IT; and intensifying competition. Some segments, like routine chemistry, begin to resemble commodity markets, where product positioning and cost per test are more critical than underlying technology. This evolving marketplace creates exciting opportunities for a variety of new instruments, reagent systems, and auxiliary products, such as specimen preparation devices, controls, and calibrators.
The 2011 Clinical Chemistry and Immunodiagnostics Markets: US, Europe, Japan&...ReportLinker.com
During the next decade, the clinical chemistry and immunodiagnostics markets will undergo significant transformation. The changes will be caused convergence of new and more stringent regulations; advances in diagnostic technologies, system engineering, automation, and IT; and intensifying competition. Some segments, like routine chemistry, will resemble commodity markets, where product positioning and cost per test are more critical than underlying technology. This evolving marketplace will create exciting opportunities for a variety of new instruments, reagent systems, and auxiliary products, such as specimen preparation devices, controls, calibrators and others."The Clinical Chemistry and Immunodiagnostics Markets" is a unique worldwide market intelligence and technology assessment study designed to help current suppliers and potential market entrants identify and evaluate emerging opportunities and develop effective strategic responses. The study explores future trends in the U.S., five major European countries and Japan; provides estimates of the specimen, test and sales volumes, as well as major suppliers' sales and market shares; compares features of leading analyzers; profiles key competitors; and identifies specific product and marketing opportunities facing suppliers during the next ten years.Contains 1,115 pages and 450 tables
European Infectious Disease Testing Market: Innovative Technologies and Emerg...ReportLinker.com
This unique report contains 1,600 pages, 580 tables and provides information not available from any other published source, including volume, sales, and leading supplier shares by test.This comprehensive European survey is designed to assist diagnostics industry executives, as well as companies planning to diversify into the dynamic and rapidly expanding infectious disease testing market, in evaluating emerging opportunities and developing effective business strategies. The report provides market segmentation analysis of over 70 diseases and viruses in five countries, assessment of emerging technologies, review of current instrumentation, as well as strategic profiles of leading suppliers and recent market entrants with innovative technologies and products. The infectious disease testing market is one of the most rapidly growing segments of the in vitro diagnostics industry, and the greatest challenge facing suppliers in the 21st century. Among the main driving forces behind the growth of this dynamic market is continuous spread of AIDS, which remains the world’s major health threat and a major factor contributing to the rise in incidence of opportunistic infections; bioterrorism; advances in molecular diagnostic technologies; and a wider availability of immunosuppressive drugs.Although for some infections the etiology is still a mystery, while for others the causative microorganisms are present in minute concentrations long before the occurrence of first clinical symptoms, recent advances in genetic engineering and detection technologies are creating exciting opportunities for highly sensitive, specific and cost-effective products.Contains 1,600 pages and 580 tables
Future Clinical Chemistry and Immunodiagnostics Markets: Growth Opportunities...ReportLinker.com
During the next decade, the clinical chemistry and immunodiagnostics markets will undergo significant transformation. The changes will be caused convergence of new and more stringent regulations; advances in diagnostic technologies, system engineering, automation, and IT; and intensifying competition. Some segments, like routine chemistry, will resemble commodity markets, where product positioning and cost per test are more critical than underlying technology. This evolving marketplace will create exciting opportunities for a variety of new instruments, reagent systems, and auxiliary products, such as specimen preparation devices, controls, calibrators and others."The Clinical Chemistry and Immunodiagnostics Markets" is a unique worldwide market intelligence and technology assessment study designed to help current suppliers and potential market entrants identify and evaluate emerging opportunities and develop effective strategic responses. The study explores future trends in the U.S., five major European countries and Japan; provides estimates of the specimen, test and sales volumes, as well as major suppliers' sales and market shares; compares features of leading analyzers; profiles key competitors; and identifies specific product and marketing opportunities facing suppliers during the next ten years.Contains 1,115 pages and 450 tables
The 2012 European Clinical Chemistry and Immunodiagnostics Markets:<br>Fra...ReportLinker.com
This unique report provides information not available from any other published source, including volume, sales, and leading supplier shares by test.This market intelligence and technology assessment report will help current suppliers and potential market entrants identify and evaluate emerging opportunities and develop effective strategic responses. The report explores future trends in five major European countries (France, Germany, Italy, Spain, UK) and Japan; provides estimates of the specimen, test and sales volumes, as well as major suppliers’ sales and market shares; compares features of leading analyzers; profiles key competitors; and identifies specific product and marketing opportunities emerging during the next five years.The clinical chemistry and immunodiagnostics markets are undergoing significant transformation, caused by convergence of new and more stringent regulations; advances in diagnostic technologies, system engineering, automation, and IT; and intensifying competition. Some segments, like routine chemistry, begin to resemble commodity markets, where product positioning and cost per test are more critical than underlying technology. This evolving marketplace creates exciting opportunities for a variety of new instruments, reagent systems, and auxiliary products, such as specimen preparation devices, controls, and calibrators.Contains 900 pages and 335 tables
During the next decade, the immunoprotein testing market will undergo significant transformation. The changes will be caused by convergence of new and more stringent regulations; advances in diagnostic technologies, system engineering, automation, and IT; and intensifying competition. Some segments will start resembling commodity markets, where product positioning and cost per test are more critical than underlying technology. This evolving marketplace will create exciting opportunities for a variety of new instruments, reagent systems, and auxiliary products, such as specimen preparation devices, controls, calibrators and others."Immunoprotein Diagnostics Market: US, Europe, Japan" is a unique worldwide market and technology assessment designed to help current suppliers and potential market entrants identify and evaluate emerging opportunities and developed effective strategic responses. The study explores future trends in the U.S., Europe, Japan; provides test volume and sales forecasts by country, market segment and individual test; compares features of leading analyzers; and profiles key competitors.Contains 297 pages and 62 tables
Innovative Infectious Disease Testing Technologies and Emerging MarketsReportLinker.com
This unique 1,900-page report contains 820 tables, and provides sales and market shares of major suppliers, by test and country, as well as test volume and sales forecasts for nearly 100 diseases and viruses. Available by country and section. The infectious disease testing market is one of the most rapidly growing segments of the in vitro diagnostics industry, and the greatest challenge facing suppliers in the 21st century. Among the main driving forces behind the growth of this dynamic market is continuous spread of AIDS, which remains the world's major health threat and a major factor contributing to the rise in incidence of opportunistic infections, threat of bioterrorism, advances in molecular diagnostic technologies, and a wider availability of immunosuppressive drugs. The infectious disease testing market is one of the most rapidly growing segments of the in vitro diagnostics industry, and the greatest challenge facing suppliers in the 21st century. Among the main driving forces behind the growth of this dynamic market is continuous spread of AIDS, which remains the world's major health threat and a major factor contributing to the rise in incidence of opportunistic infections, threat of bioterrorism, advances in molecular diagnostic technologies, and a wider availability of immunosuppressive drugs. Although for some infections the etiology is still a mystery, while for others the causative microorganisms are present in minute concentrations long before the occurrence of first clinical symptoms, recent advances in genetic engineering and detection technologies are creating exciting opportunities for highly sensitive, specific and cost-effective products.This comprehensive worldwide survey is designed to assist diagnostics industry executives, as well as companies planning to diversify into the dynamic and rapidly expanding infectious disease testing market, in evaluating emerging opportunities and developing effective business strategies. The report provides a market segmentation analysis of over 70 diseases and viruses in seven countries, assessment of emerging technologies, review of current instrumentation, as well as strategic profiles of leading suppliers and recent market entrants with innovative technologies and products.
As medical understanding of the genotype/phenotype correlation of a disease becomes clearer, genetic testing can be expected to become a mainstay in the clinical setting. While the application of genetic testing to the clinical setting is very much in line with the larger medical goals of preventative and personalized medicine, there are many unanswered questions with regard to genetic testing.
Speakers: Dr. Mansoor Mohammed, Genomics Portraits Inc., Dr. Brian Underdown, Managing Director, MDS Capital, Dr. June Carroll, Sydney G. Frankfort Chair in Family Medicine Mt.Sinai Hospital, Dr. Peter N. Ray, Head, Molecular Genetics Department of Paediatric Laboratory Medicine. HSC Professor, Molecular and Medical Genetics, University of Toronto
Western Blotting Market, By Product Type (Electrophoresis Blotting Systems (Automated Dry Blotting Systems, Semi-Dry Blotting Systems, Traditional Wet Transfer Blotting Systems), Reagents & Kits (Chromogenic Reagents Kits, Chemiluminescent Reagents Kits)(Horseradish Peroxidase (HRP) Substrate, Alkaline Phosphatase (AP) Substrate), Fluorescent Reagents, Antibodies(Primary Antibody, Secondary Antibody),Buffer Kits, Transfer Membranes), By Application (Scientific Research, Medical Diagnostics, Agricultural Application, Food & Beverages, Other Applications), By End User (Diagnostic Laboratories, Research Institutions, Pharmaceutical & Biotechnology Companies), and By Region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2019 - 2027
This report analyzes the worldwide markets for Molecular Diagnostics in US$ million by the following segments: Infectious Disease Testing, Pharmacogenomics, and Cancer Screening. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2007 through 2015. A seven-year historic analysis is also provided for these markets. The report profiles 101 companies including many key and niche players such as Abbott Laboratories, Abbott Molecular, Applera Corporation, Celera, Biom
Multiplex Assays in Translational Medicine: Technologies, Applications, and F...ReportLinker.com
The development and growth of assay technologies has pushed translational medicine into a category unto itself. In a broad perspective on this field, this new report:Defines translational medicine by giving some historical background as well as providing personal definitions from experts in the field Discusses the evolution of assay technologies Reviews currently available assay technologies that apply directly to translational medicine Describes and evaluates current applications of these technologies Provides case studies of clinicians currently using this technology in their research Discusses future directions of assay technologies for translational medicine Gives input from the FDA on translation medicine and assay technologies Provides interviews from experts in the field of both translational medicine and specific assay technologies Profiles premier companies active in the field Assay technologies have been evolving since scientists first discovered they could measure glucose, insulin, and several hormones in the blood to help them diagnose disease. Early instruments such as the Ames Reflectance Meter, used for detecting glucose levels, have morphed into such sophisticated systems as flow cytometers. The Human Genome Project provided the basics for researchers to launch into the field of human genomics and they needed the tools to accomplish this. DNA microarrays allowed for massively parallel gene expression analyses. Scientists soon discovered that while the genomewide assays were extremely valuable, there were genes of interest that they had difficulty measuring when they got hundreds of data points from a microarray. Low- to mid-density assays have allowed scientists to pinpoint the genetic code for a variety of uses, from genetic heredity studies to drug metabolism and patient stratification.
What are the liquid biopsy fundamentals? What are the goals of liquid biopsy? What are the market trends in liquid biopsy? Who's investing in liquid biopsy? What biomarkers are driving liquid biopsy?
Global Molecular Diagnostics Market: Innovative Technologies and Emerging Bus...ReportLinker.com
This unique seven-country report contains 1,050 pages, 96 tables, and is designed to help current suppliers and potential market entrants identify and evaluate major business opportunities emerging in the molecular diagnostics market during this decade. The report explores business and technological trends in the US, five major European countries, (France, Germany, Italy, Spain, UK) and Japan; provides 5- and 10-year test volume/sales forecasts; estimates shares of leading competitors; compares features of major analyzers; profiles leading market players; and identifies specific product and business opportunities facing instrument and consumable suppliers during the next ten years.The molecular diagnostics market is unquestionably the most rapidly growing segment of the in vitro diagnostics industry. The next ten years will witness significant developments in reagent systems and automation, as well as introduction of a wide range of new products that will require innovative marketing approaches. The rate of market penetration into routine clinical laboratories, however, will depend on the introduction of cost-effective and automated systems with amplification methods. In order to successfully capitalize on the opportunities presented by the molecular diagnostics market, many companies are already exploiting new DNA probe and biochip technologies as corporate strategic assets, managed in support of business and marketing strategies. Integrating new technology planning with business and corporate strategies will be one of the most challenging tasks for diagnostics companies during the next ten years.
Competing in the European Clinical Chemistry and Immunodiagnostic Markets: Fr...ReportLinker.com
This new 900-page five-country market intelligence and technology assessment report from Venture Planning Group will help current suppliers and potential market entrants identify and evaluate emerging opportunities and develop effective strategic responses. The report explores future trends in major European countries (France, Germany, Italy, Spain, UK); provides estimates of the specimen, test and sales volumes, as well as major suppliers sales and market shares; compares features of leading analyzers; profiles key competitors; and identifies specific product and marketing opportunities emerging during the next five years.The clinical chemistry and immunodiagnostic markets are undergoing significant transformation, caused by convergence of new and more stringent regulations; advances in diagnostic technologies, system engineering, automation, and IT; and intensifying competition. However, this evolving marketplace creates exciting opportunities for a variety of new instruments, reagent systems, and auxiliary products, such as specimen preparation devices, controls, and calibrators.
During the next decade, the immunoprotein testing market will undergo significant transformation. The changes will be caused by convergence of new and more stringent regulations; advances in diagnostic technologies, system engineering, automation, and IT; and intensifying competition. Some segments will start resembling commodity markets, where product positioning and cost per test are more critical than underlying technology. This evolving marketplace will create exciting opportunities for a variety of new instruments, reagent systems, and auxiliary products, such as specimen preparation devices, controls, calibrators and others."Immunoprotein Diagnostics Market: US, Europe, Japan" is a unique worldwide market and technology assessment designed to help current suppliers and potential market entrants identify and evaluate emerging opportunities and developed effective strategic responses. The study explores future trends in the U.S., Europe, Japan; provides test volume and sales forecasts by country, market segment and individual test; compares features of leading analyzers; and profiles key competitors.Contains 297 pages and 62 tables
Innovative Infectious Disease Testing Technologies and Emerging MarketsReportLinker.com
This unique 1,900-page report contains 820 tables, and provides sales and market shares of major suppliers, by test and country, as well as test volume and sales forecasts for nearly 100 diseases and viruses. Available by country and section. The infectious disease testing market is one of the most rapidly growing segments of the in vitro diagnostics industry, and the greatest challenge facing suppliers in the 21st century. Among the main driving forces behind the growth of this dynamic market is continuous spread of AIDS, which remains the world's major health threat and a major factor contributing to the rise in incidence of opportunistic infections, threat of bioterrorism, advances in molecular diagnostic technologies, and a wider availability of immunosuppressive drugs. The infectious disease testing market is one of the most rapidly growing segments of the in vitro diagnostics industry, and the greatest challenge facing suppliers in the 21st century. Among the main driving forces behind the growth of this dynamic market is continuous spread of AIDS, which remains the world's major health threat and a major factor contributing to the rise in incidence of opportunistic infections, threat of bioterrorism, advances in molecular diagnostic technologies, and a wider availability of immunosuppressive drugs. Although for some infections the etiology is still a mystery, while for others the causative microorganisms are present in minute concentrations long before the occurrence of first clinical symptoms, recent advances in genetic engineering and detection technologies are creating exciting opportunities for highly sensitive, specific and cost-effective products.This comprehensive worldwide survey is designed to assist diagnostics industry executives, as well as companies planning to diversify into the dynamic and rapidly expanding infectious disease testing market, in evaluating emerging opportunities and developing effective business strategies. The report provides a market segmentation analysis of over 70 diseases and viruses in seven countries, assessment of emerging technologies, review of current instrumentation, as well as strategic profiles of leading suppliers and recent market entrants with innovative technologies and products.
As medical understanding of the genotype/phenotype correlation of a disease becomes clearer, genetic testing can be expected to become a mainstay in the clinical setting. While the application of genetic testing to the clinical setting is very much in line with the larger medical goals of preventative and personalized medicine, there are many unanswered questions with regard to genetic testing.
Speakers: Dr. Mansoor Mohammed, Genomics Portraits Inc., Dr. Brian Underdown, Managing Director, MDS Capital, Dr. June Carroll, Sydney G. Frankfort Chair in Family Medicine Mt.Sinai Hospital, Dr. Peter N. Ray, Head, Molecular Genetics Department of Paediatric Laboratory Medicine. HSC Professor, Molecular and Medical Genetics, University of Toronto
Western Blotting Market, By Product Type (Electrophoresis Blotting Systems (Automated Dry Blotting Systems, Semi-Dry Blotting Systems, Traditional Wet Transfer Blotting Systems), Reagents & Kits (Chromogenic Reagents Kits, Chemiluminescent Reagents Kits)(Horseradish Peroxidase (HRP) Substrate, Alkaline Phosphatase (AP) Substrate), Fluorescent Reagents, Antibodies(Primary Antibody, Secondary Antibody),Buffer Kits, Transfer Membranes), By Application (Scientific Research, Medical Diagnostics, Agricultural Application, Food & Beverages, Other Applications), By End User (Diagnostic Laboratories, Research Institutions, Pharmaceutical & Biotechnology Companies), and By Region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2019 - 2027
This report analyzes the worldwide markets for Molecular Diagnostics in US$ million by the following segments: Infectious Disease Testing, Pharmacogenomics, and Cancer Screening. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2007 through 2015. A seven-year historic analysis is also provided for these markets. The report profiles 101 companies including many key and niche players such as Abbott Laboratories, Abbott Molecular, Applera Corporation, Celera, Biom
Multiplex Assays in Translational Medicine: Technologies, Applications, and F...ReportLinker.com
The development and growth of assay technologies has pushed translational medicine into a category unto itself. In a broad perspective on this field, this new report:Defines translational medicine by giving some historical background as well as providing personal definitions from experts in the field Discusses the evolution of assay technologies Reviews currently available assay technologies that apply directly to translational medicine Describes and evaluates current applications of these technologies Provides case studies of clinicians currently using this technology in their research Discusses future directions of assay technologies for translational medicine Gives input from the FDA on translation medicine and assay technologies Provides interviews from experts in the field of both translational medicine and specific assay technologies Profiles premier companies active in the field Assay technologies have been evolving since scientists first discovered they could measure glucose, insulin, and several hormones in the blood to help them diagnose disease. Early instruments such as the Ames Reflectance Meter, used for detecting glucose levels, have morphed into such sophisticated systems as flow cytometers. The Human Genome Project provided the basics for researchers to launch into the field of human genomics and they needed the tools to accomplish this. DNA microarrays allowed for massively parallel gene expression analyses. Scientists soon discovered that while the genomewide assays were extremely valuable, there were genes of interest that they had difficulty measuring when they got hundreds of data points from a microarray. Low- to mid-density assays have allowed scientists to pinpoint the genetic code for a variety of uses, from genetic heredity studies to drug metabolism and patient stratification.
What are the liquid biopsy fundamentals? What are the goals of liquid biopsy? What are the market trends in liquid biopsy? Who's investing in liquid biopsy? What biomarkers are driving liquid biopsy?
Global Molecular Diagnostics Market: Innovative Technologies and Emerging Bus...ReportLinker.com
This unique seven-country report contains 1,050 pages, 96 tables, and is designed to help current suppliers and potential market entrants identify and evaluate major business opportunities emerging in the molecular diagnostics market during this decade. The report explores business and technological trends in the US, five major European countries, (France, Germany, Italy, Spain, UK) and Japan; provides 5- and 10-year test volume/sales forecasts; estimates shares of leading competitors; compares features of major analyzers; profiles leading market players; and identifies specific product and business opportunities facing instrument and consumable suppliers during the next ten years.The molecular diagnostics market is unquestionably the most rapidly growing segment of the in vitro diagnostics industry. The next ten years will witness significant developments in reagent systems and automation, as well as introduction of a wide range of new products that will require innovative marketing approaches. The rate of market penetration into routine clinical laboratories, however, will depend on the introduction of cost-effective and automated systems with amplification methods. In order to successfully capitalize on the opportunities presented by the molecular diagnostics market, many companies are already exploiting new DNA probe and biochip technologies as corporate strategic assets, managed in support of business and marketing strategies. Integrating new technology planning with business and corporate strategies will be one of the most challenging tasks for diagnostics companies during the next ten years.
Competing in the European Clinical Chemistry and Immunodiagnostic Markets: Fr...ReportLinker.com
This new 900-page five-country market intelligence and technology assessment report from Venture Planning Group will help current suppliers and potential market entrants identify and evaluate emerging opportunities and develop effective strategic responses. The report explores future trends in major European countries (France, Germany, Italy, Spain, UK); provides estimates of the specimen, test and sales volumes, as well as major suppliers sales and market shares; compares features of leading analyzers; profiles key competitors; and identifies specific product and marketing opportunities emerging during the next five years.The clinical chemistry and immunodiagnostic markets are undergoing significant transformation, caused by convergence of new and more stringent regulations; advances in diagnostic technologies, system engineering, automation, and IT; and intensifying competition. However, this evolving marketplace creates exciting opportunities for a variety of new instruments, reagent systems, and auxiliary products, such as specimen preparation devices, controls, and calibrators.
There are an estimated 33.3 million people living with HIV (the virus which causes AIDS) worldwide and approximately 2.6 million people are newly-infected each year. While the Asian and African regions account for more than 90% of the HIV-infected population (with the highest number in Sub-Saharan Africa), the U.S. and European regions make up greater than 60% of the HIV testing market. This TriMark Publications report provides a comprehensive examination of the HIV/AIDS testing market, a specific segment of the in vitro diagnostics (IVD) market as it relates to infectious diseases. It examines the available and emerging technologies being utilized by the HIV testing field, defines the dollar volume of sales'both in the U.S. and worldwide'and analyzes the factors that influence the size and growth of the market. The chief HIV testing assays, i.e., predictive, screening, prognostic, monitoring, pharmacogenomic and theranostic, are covered thoroughly, as are high-growth applications in different clinical diagnostic areas and expanding markets, such as employee screening, emergency medicine and satellite clinic testing. Additionally, this analysis covers the following areas in details: enzyme-linked immunosorbent assay (ELISA), antibody/p24 antigen test (fourth-generation test), Western blot assay, line immunoassays, indirect fluorescent antibody (IFA) assay, nucleic acid tests for infectious diseases, and the emerging technologies related to HIV and AIDS diagnosis. Moreover, this study also provides a thorough analysis of the companies known to be marketing, manufacturing or developing HIV testing products, as well as provides detailed tables and figures covering HIV testing markets around the globe.
Europe DNA Sequencing Products Market by Product Type, Distribution Channel, ...IMARC Group
The Europe DNA sequencing products market size reached US$ 1.9 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 4.7 Billion by 2028, exhibiting a growth rate (CAGR) of 16.7% during 2023-2028.
More Info:- https://www.imarcgroup.com/europe-dna-sequencing-products-market
There will be a steady increase in demand for new diagnostic testing services in the next five-year period, along with pressures to improve the quality of healthcare delivered in the clinic and also to lower its costs. Clinical labs experienced a substantial growth during the last decade. The emphasis in this TriMark Publications report is on those companies that are actively developing and marketing high-growth diagnostic testing technologies in the clinical hospital market. It defines the dollar volume of sales, both worldwide and in the U.S., of the market and analyzes the factors that influence the size and growth of market segments. The study goes on to discuss in detail trends that have developed which have stimulated this market, and also comments in detail patterns of information processing in the high-growth diagnostic testing technologies. Moreover, this exanimation provides an overview of the diagnostic testing market, including the latest information regarding exciting new products and industry trends. It will not only quantify but also qualify the market high-growth segments as an area of research and investment. Forecasts of the market and analyses of products in the worldwide prescriptions market will provide a basis for understanding the significance of past developments and future possibilities within this therapeutic category.
Veterinary Molecular Diagnostics Market PPT: Overview, Dynamics, Trends, Segm...IMARC Group
The global veterinary molecular diagnostics market size reached US$ 690.8 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 1,391.9 Million by 2032, exhibiting a growth rate (CAGR) of 7.9% during 2024-2032.
More Info:- https://www.imarcgroup.com/veterinary-molecular-diagnostics-market
Veterinary Molecular Diagnostics Market by Product Type, Distribution Channel...IMARC Group
The global veterinary molecular diagnostics market size reached US$ 634.9 Million in 2022. Looking forward, IMARC Group expects the market to reach US$ 1,064.8 Million by 2028, exhibiting a growth rate (CAGR) of 8.8% during 2023-2028.
More Info:- https://www.imarcgroup.com/veterinary-molecular-diagnostics-market
Blood Culture Test Market PPT: Demand, Trends and Business Opportunities 2023-28IMARC Group
The global blood culture test market size reached US$ 4.7 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 7.7 Billion by 2028, exhibiting a growth rate (CAGR) of 8.5% during 2023-2028.
More Info:- https://www.imarcgroup.com/blood-culture-test-market
The polymerase chain reaction (PCR) approach has been demonstrated to be effective in pharmaceutical and biotechnology research, as well as microbiological quality control. The approach is also used in genetic engineering.
The global sexually transmitted disease (STD) diagnostics market size reached US$ 104.1 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 159.5 Billion by 2032, exhibiting a growth rate (CAGR) of 4.71% during 2024-2032.
More Info:- https://www.imarcgroup.com/sexually-transmitted-disease-diagnostics-market
Nanopore Technologies Market PPT: Demand, Trends and Business Opportunities 2...IMARC Group
The global nanopore technologies market size reached US$ 244.4 Million in 2022. Looking forward, IMARC Group expects the market to reach US$ 511.5 Million by 2028, exhibiting a growth rate (CAGR) of 12.4% during 2023-2028.
More Info:- https://www.imarcgroup.com/nanopore-technologies-market
5 Cutting-Edge Trends in Molecular DiagnosticsBruce Carlson
Despite the focus on novelty in this field, it is near 2 decades old. Yet a lot is changing. A look at a few trends that could change molecular diagnostics.
DNA Sequencing Products Market by Product Type, Distribution Channel, End Use...IMARC Group
The global DNA sequencing products market size reached US$ 6.3 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 11.4 Billion by 2028, exhibiting a growth rate (CAGR) of 9.76% during 2023-2028.
More Info:- https://www.imarcgroup.com/dna-sequencing-products-market
Cell-Based Assay Market 2022-2027: Size, Share, Trends, Analysis & Research ...IMARC Group
According to the latest report by IMARC Group, that the global cell-based assay market size reached US$ 18.9 Billion in 2021. Cell-based assay or cellular assay is an analytical method to determine the concentration of a substance by observing its effects on living organisms (in vivo) or tissues (in vitro). It provides a closer representation of the real-life model, which helps to verify the biological activity of drugs and determine whether the antibodies produced by the patient are neutralizing the drug.
Similar to Competing in the European Molecular Diagnostics Market: France, Germany, Italy, Spain, UK (20)
Smartphones: When is the first and last time you check yours?ReportLinker.com
Nearly half (46%) of Americans say they check their smartphones as soon as they wake up, while they’re still in bed, according to ReportLinker’s survey results. This is especially true of Millennials, 66% of whom say it’s the first thing they do before getting out of bed.
75% of Ameircans say they keep their smartphones active all day and night, and a staggering 83% of Millennials say they do.
In fact, disconnecting can be hard. More than half of Americans say their last check is right before bed – and 13% say they disconnect only after they’ve gotten into bed for the night. Even after they fall asleep, about 10% say they’ll wake up and check it during the night.
This graphic shows Samsung's customers are still loyal: 86% of Samsung Customers would consider Samsung next time they upgrade their smartphone. More info on reportlinker.com/inisght
Allegra Strategies is proud to release the 2012 report on European branded coffee shop market, providing comprehensive research on this fast developing market.The ProjectCaf
Allegra's definitive annual study on the UK branded coffee shop market is now available; with insight from over 25,000 consumers the report provides an authoritative view of the market.Drawing on more than 12 years in-depth research, it is considered to be the bible of the coffee sector.KEY AREAS COVERED' Market size and growth projections for the total UK market' Impact of recent economic downturn on trading performance' Key player profiles, including financial performance, pricing analysis and forecasts' Importance of ethical and sustainability issues' Key success factors and market trends' Opportunities and challenges for suppliers' Consumer coffee consumption patterns' Consumer brand awareness and perceptions of key players' Differences between customer demographics, including age, gender, occupation and location by the reportSOURCE OF INFORMATION' Interviews with CEOs, managing directors, senior managers and store managers of major industry players, including:' leading UK coffee and food-focused chains' major coffee roasters and key equipment suppliers' non-specialist players including department stores, supermarkets, bookstores' leading property companies, letting agents and landlords' local authorities' Online surveys with UK coffee shop visitors' Desk research including: News articles and trade press, the Internet and company websites,industry associations, published accounts, data supplied by operators' In-store observations and analysis
Wireless Infrastructure: Market Shares, Strategies, and Forecasts, Worldwide,...ReportLinker.com
WinterGreen Research announces that it has published a new study Wireless Infrastructure: Market Shares, Strategy, and Forecasts, Worldwide, 2013 to 2019. Next generation mission critical systems are leveraging new technology. The 2013 study has 554 pages, 245 tables and figures. Worldwide Wireless Infrastructure markets are poised to achieve significant growth as Building out core networks and backhaul for smart phones.A smart phone is not very smart if the infrastructure can't support its applications. In response to the high growth smart phone markets, wireless infrastructure promises to grow dramatically in the near term.. Wireless Infrastructure technologies include WiMax, LTE, 4G and HSPA. These technologies are driving much higher capacity from the base station back to the fiber core. Fiber core is putting extreme pressure on provider's infrastructure and backhaul networks.WinterGreen Research predicts that the dramatic growth of wireless infrastructure is based on the growth of smart phones to a one trillion market by 2019, serving an installed base of 8.5 billion, many people having more than one smart phone. Wireless infrastructure markets at $58 billion in 2012 will be $163 billion by 2019, new markets evolved because of the value that apps provide to smart phones, mobile devices, tablets, and the Internet of things.According to Susan Eustis, lead author of the study, 'Wireless Infrastructure is being installed to upgrade core networks and upgrade backhaul and base stations to make systems more modern. Infrastructure for the Internet and for smart mobile devices creates demand for more sophisticated web development and web applications that in turn depend on more sophisticated infrastructure. Everything is going mobile. This evolution is driven by mobile smart phones and tablets that provide universal connectivity. Modern systems represent a significant aspect of Internet market evolution.'The proportions of wireless infrastructure market industry segments are expected to remain much as they are, with the small cells and femtocells achieving strong growth on the access side, the core infrastructure must be upgraded to support the added backhaul backbone infrastructure. Wireless apps are expected to achieve $37 trillion revenue by 2019. This unbelievable growth occurs as the Internet is expanded to implement the interconnection of everything.Digital devices proliferate, machine to machine capabilities vastly expand instrumentation. The digital devices become the engine of a world economy, with apps collecting pennies a day for millions of apps from 8.5 billion people with smart phones by 2019.
Global Electric Resistance Welded Pipes IndustryReportLinker.com
This report analyzes the worldwide markets for Electric Resistance Welded Pipes in Thousand Tons by the following Product Segments: Mechanical Steel Tubing, Structural Tubing, Structural Steel Pipes, Pressure Tubing, Standard Pipes, Oil Country Tubular Goods, and Line Pipes. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East, and Latin America. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets. The report profiles 181 companies including many key and niche players such as Al Jazeera Steel Products Company SAOG, Arabian Pipes Company, ArcelorMittal SA, ERW Pipes Portfolio of ArcelorMittal ChelPipe, Choo Bee Metal Industries Berhad, EVRAZ North America, JFE Steel Corporation, Maharashtra Seamless Limited, Melewar Industrial Group Berhad, Nippon Steel & Sumitomo Metal Corporation, Northwest Pipe Company, OAO TMK, TMK IPSCO, PT Bakrie Pipe Industries, Salzgitter Mannesmann Line Pipe GmbH, Tata Steel Europe, Techint Group SpA, Tenaris S.A., TenarisSiderca, Ternium S.A., United States Steel Corporation, United Metallurgical Company /OMK, Welspun Corp Ltd., Wheatland Tube Company, and Select Products of Wheatland Tube Company. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.
This report analyzes the worldwide markets for Wireless Gaming in US$ Million by the following Product Segments: Messaging Based Wireless Gaming, Browser/Web Based Wireless Gaming, and Downloadable Wireless Gaming. The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. The report profiles 90 companies including many key and niche players such as Blockdot, Inc., DeNA Co., Ltd., Electronic Arts, Inc., Gameloft SA,GAMEVIL, GREE International, Inc., Glu Mobile Inc., GigaMedia Limited, HandyGames, I-play, Itsmy
Hyperalgesia Global Clinical Trials Review, H1, 2013ReportLinker.com
Hyperalgesia Global Clinical Trials Review, H1, 2013
Summary
GlobalData's clinical trial report, 'Hyperalgesia Global Clinical Trials Review, H1, 2013" provides data on the Hyperalgesia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hyperalgesia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Hyperalgesia. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Genital Herpes Global Clinical Trials Review, H1, 2013ReportLinker.com
Genital Herpes Global Clinical Trials Review, H1, 2013
Summary
GlobalData's clinical trial report, 'Genital Herpes Global Clinical Trials Review, H1, 2013" provides data on the Genital Herpes clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Genital Herpes. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Genital Herpes. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
The Future of Direct Communications Technologies and Proximity-based Applicat...ReportLinker.com
Overview: There are a number of technologies that may be deployed that all provide the ability for devices to "discover" one another, although over different distances ranging from centimeters (Near Field Communications), to meters (Bluetooth), to 10s of meters (Wi-Fi). They also all provide the ability for the devices to communicate directly with one another without a centralized network. Some of these use direct communication as their primary mode of communication e.g. NFC or RFID. Others are more traditional networks which provide direct communication ability as an adjunct to their primary network functions e.g. LTE-Direct or Wi-Fi Direct. Most of the short-term drivers for proximity-based services will be mobile advertising and social networking, especially friend-finder services or dating services, and gaming. In the longer term, other applications will come into play within the scope of the so called Internet of Things. The challenge and opportunity for network operators will be to develop new user scenarios and even new business models to generate revenues from these services. This research uncovers opportunities that will be both beneficial and disruptive to the existing ecosystem and value chain. This research is must reading for any company that is considering offerings within proximity and direct communications and any company that wants to stay ahead of the crowd in terms of preparation for these disruptive technologies. Target Audience: ' Mobile network operators' Industry verticals of all types' Wireless device manufacturers' Network infrastructure companies' Advertising agencies, brands, and merchants' Social networks, advertising, and content providers' Proximity, location, and direct communications vendors Key Report Benefits: ' Market forecasts for each significant technology/solution approach' Recognize the upcoming role and importance of LTE Direct compared to other solutions' Analysis of the major vendors focused on proximity and direct communications solutions' Understand the relationship between proximity, direct communications and the Internet of Things' Understand the technical and business-related differences between proximity/presence and location' Identify each of the major technologies/solutions for proximity detection, location determination, and direct communications' Evaluation of the market for major applications including public safety, social networking, advertising, the Internet of Things, and general location services Select Companies in Report: ' 3M Company' Alcatel-Lucent' iSIGN' LG' Nokia' Samsung' Qualcomm' Verizon Wireless
Bradycardia Global Clinical Trials Review, H1, 2013ReportLinker.com
Bradycardia Global Clinical Trials Review, H1, 2013
Summary
GlobalData's clinical trial report, 'Bradycardia Global Clinical Trials Review, H1, 2013" provides data on the Bradycardia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Bradycardia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Bradycardia. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Acid Indigestion / Heartburn/ Pyrosis Global Clinical Trials Review, H1, 2013
Summary
GlobalData's clinical trial report, 'Acid Indigestion / Heartburn/ Pyrosis Global Clinical Trials Review, H1, 2013" provides data on the Acid Indigestion / Heartburn/ Pyrosis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Acid Indigestion / Heartburn/ Pyrosis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Acid Indigestion / Heartburn/ Pyrosis. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
The biomass market suffered during the economic downturn in the face of low coal prices, logistic barriers and supply issues. 2010 saw more movement in the sector as coal prices are beginning to rise once again making co-firing coal plants with biomass more attractive. Furthermore, the biomass component of a coal-fired plant may be eligible for feed-in tariff or count towards renewable portfolio standards.Most of these plants rely on wood pellets, often transported at great distance, rather than wood chips or other less dense biomass sources. In the wood pellets market, supplies from the US and Canada are cheaper than their European counterparts and thus North America is a major suppli- ers for European biomass plants. CIS countries, Russia, Australia and South Africa have entered as significant suppliers, which if they could ramp up supply, could be serious competitors to the US and Canada. Or in the case of Russia, resolve supply delay issues, could be one of the biggest players in the market.
Competing in the European Molecular Diagnostics Market: France, Germany, Italy, Spain, UK
1. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Competing in the European Molecular Diagnostics Market: France,
Germany, Italy, Spain, UK
Published on February 2013
Report Summary
This new 970-page comprehensive five-country report from Venture Planning Group is designed to help current suppliers and
potential market entrants identify and evaluate the major business opportunities emerging in the European molecular diagnostics
market during the next five years. The report explores business and technological trends in major European countries (France,
Germany, Italy, Spain, UK); provides 5-year test volume/sales forecasts; estimates shares of leading competitors; compares features
of major analyzers; profiles leading market players; and identifies specific product and business opportunities facing instrument and
consumable suppliers during the next five years.
The $4.5 billion molecular diagnostics market is unquestionably the most rapidly growing segment of the in vitro diagnostics industry.
The next five years will witness significant developments in reagent systems and automation, as well as introduction of a wide range
of new products that will require innovative marketing approaches. The rate of market penetration into routine clinical laboratories,
however, will depend on the introduction of and cost-effective automated systems with amplification methods.
In order to successfully capitalize on the opportunities presented by the molecular diagnostics market, many companies are already
exploiting new technologies as corporate strategic assets, managed in support of business and marketing strategies. Integrating new
technology planning with business and corporate strategies will be one of the most challenging tasks for diagnostics companies
during the next five years.
Table of Content
Table of Contents
Introduction
Worldwide Market And Technology Overview
A. DNA Sequencing
1. Introduction
2. Sequencing Methods
3. Autoradiography
4. The Human Genome Project
5. Sequencing Automation
6. Image Scanners
7. Fluorescent Detection
8. Gene Profiling
9. Gene Expression
10. Polymorphism Screening
11. Protein Interaction Networks
B. DNA And RNA Probe Technology
1. Basic Principles
2. Probe Preparation
Competing in the European Molecular Diagnostics Market: France, Germany, Italy, Spain, UK (From Slideshare) Page 1/18
2. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
3. The DNA Probe Test
a. Sample Preparation
b. Hybridization
c. Separation
d. Detection/Measurement
4. Test Formats
a. Filter Hybridization
b. Southern Blot
c. Northern Blot
d. In Situ Hybridization
e. Others
5. Labeling Techniques
6. Amplification Methods
- Polymerase Chain Reaction
- Temperature Cyclers
- PCR Variations
* Immuno-PCR
* QC-PCR
* DAP-PCR
- Strand Displacement Activation
- TMA
- Ligase Chain Reaction
- Branched DNA
- Hybridization Protection Assay
- Nucleic-Acid Sequence-Based Amplification
- Self-Sustained Sequence Replicase
- Others
- Ampliprobe
- CAR
- CAS
- CPT
- Dendritic Polymer Technology
- ISO-CR
- LAT
- Probe Networks
- RAMP
- Repair Chain Reaction
- Rolling Circles
- Sequence Independent Gene Amplification
- Sequence Initiation Reaction
- SISPA
- Solid Phase Amplification
C. Detection Technologies
1. Radioactive Methods
a. Overview
b. Major Isotopes
- P-32
- S-35
Competing in the European Molecular Diagnostics Market: France, Germany, Italy, Spain, UK (From Slideshare) Page 2/18
3. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
- H-3
- I-125
2. Non-Isotopic Methods
a. Enzymatic Labels
b. Chemical Labeling
- Indirect Chemical Labeling
- Direct Chemical Labeling
c. Fluorescence
d. Chemiluminescence
e. Electrical Conductivity
D. Instrumentation Review
1. Abbott LCx
2. Beckman Coulter/Biomek FK
3. Becton Dickinson SDA
4. Bio-Rad GeneScope
5. Gen-Probe Tigris
6. Roche Cobas Amplicor
7. Tecan LS Series
E. Biochips: Genosensors, Microarrays, and
Labs-on-the-Chip
- Liquid Transportation and Mixing
- Separation
- Reaction
- Detection
F. Pharmacogenomics
G. Major Applications
1. Microbiology/Infectious Diseases
a. Overview
b. Major Infectious Diseases
* AIDS
- Structure and Composition
- Classification
- AIDS Origins
- Animal Lentivirus Systems
- Virus Receptors
- HIV Infections in Humans
- Pathogenesis and Pathology
- CD4T Lymphocytes and Memory Cells
- Monocytes and Macrophages
- Lymphoid Organs
- Neural Cells
- Viral Coinfections
- Clinical Findings
- Plasma Viral Load
- Pediatric AIDS
- Neurologic Disease
- Opportunistic Infections
- Cancer
Competing in the European Molecular Diagnostics Market: France, Germany, Italy, Spain, UK (From Slideshare) Page 3/18
4. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
- Immunity
- Virus Isolation
- Serology
- Viral Nucleic Acid/Antigen Detection
- Epidemiology
- Worldwide Spread of AIDS
- United States
- Routes of Transmission
- DNA Probes
- Overview
- Quantitative PCR
- In Situ PCR
- Needed Improvements
- Viral Load/Drug Resistance Testing
- Genotype and Phenotype Testing
- Blood Banking Considerations
* Adenovirus
- Background
- Diagnostic Tests
- Vaccines and Drugs
- Adeno-Associated Viruses (AAV)
* Anthrax/Bacillus Anthracis
- Background
- Diagnostic Tests
- Vaccines and Drugs
* Babesiosis
- Background
* BEA and Other Bartonella Diseases
- Background
- Diagnostic Tests
- Vaccines and Drugs
* Chagas Disease
- Background
* Campylobacter
- Background
- Diagnostic Tests
- Culture Identification
- Vaccines and Drugs
* Chlamydia
- Background
- Chlamydia psittaci
- Chlmaydia pneumoniae
- Chlamydia trachomatis
- Diagnostic Tests
- Vaccines and Drugs
* Creutzfeldt-Jakob's Disease
- Background
- Blood Transmission
Competing in the European Molecular Diagnostics Market: France, Germany, Italy, Spain, UK (From Slideshare) Page 4/18
5. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
- Diagnostic Tests
- Major Commercial and Academic Players
- Bayer
- Disease Sciences/Bi - Tec Global
- Imperial College School of Medicine
- Ortho-Clinical Diagnostics
- Pall
- ProMetic Life Sciences
- Proteome Sciences/Idexx
- Q-One Biotech
- Serono
- U.S. Agricultural Research Service
- Drugs
- Vaccines
* Cytomegalovirus
- Background
- Chorioretinitis
- Gastrointestinal
- Central Nervous System Disease
- Diagnostic Tests
- Vaccines and Drugs
* Ebola Virus
- Background
- Epidemiology
- Clinical Syndromes
- Diagnostic Tests
- Vaccines and Drugs
* EchoVirus
- Background
- Acute Aseptic Meningitisis
- Encephalitis
- Exanthems
- Respiratory Disease
- Myopericarditis
- Neonatal Infections
- Diagnostic Tests
- Vaccines and Drugs
* Encephalitis
- Background
- Diagnostic Tests
- Vaccines and Drugs
* Enteroviruses
- Background
- Diagnostic Tests
- Viral Isolation and Identification
- Antibody Tests
- Vaccines and Drugs
* Epstein-Barr Virus
Competing in the European Molecular Diagnostics Market: France, Germany, Italy, Spain, UK (From Slideshare) Page 5/18
6. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
- Background
- Diagnostic Tests
- Vaccines and Drugs
* Gonorrhea
- Background
- Diagnostic Tests
- Vaccines and Drugs
* Hepatitis
- Hepatitis A
- Hepatitis B
- Structure and Composition
- Replication
- Hepatitis C
- Hepatitis D (Delta)
- Hepatitis E
- Hepatitis G
- Hepatitis Infections Pathology
- Clinical Findings
- Laboratory Tests
- Hepatitis A
- Hepatitis B
- Hepatitis C
- Hepatitis D
- Hepatitis E
- Virus-Host Immune Reactions
- Epidemiology
- Hepatitis A
- Hepatitis B
- Hepatitis C
- Hepatitis D (Delta)
- Vaccines and Drugs
* Herpes Simplex Virus
- Background
- Diagnostic Tests
- Vaccines and Drugs
* Legionella
- Background
- Diagnostic Tests
- Vaccines and Drugs
* Lyme Disease
- Background
- Clinical Description
- Clinical Case Definition
- Laboratory Criteria for Diagnosis
- Case Classification
- Diagnostic Tests
- Vaccines and Drugs
* Malaria
Competing in the European Molecular Diagnostics Market: France, Germany, Italy, Spain, UK (From Slideshare) Page 6/18
7. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
* Mycoplasma
- Background
- Ureaplasma Urealyticum & Mycoplasma
Hominis
- Diagnostic Tests
- Vaccines and Drugs
* Papillomaviruses/HPV
- Background
- HPV in Cancer
- Cervical Neoplasm
- Diagnostic Tests
- Vaccines and Drugs
- Prevention
* Parvovirus B19
- Background
- Microbiology
- Epidemiology
- Clinical Syndromes
- Erythema Infectiosum (Slapped Cheek)
- Adult Polyarthropathy
- Transient Aplastic Crisis
- Transient Pancytopenia
- Red Cell Aplasia in Immunocompromised
- Perinatal Infections
- Diagnostic Test
- Vaccines and Drugs
* Pneumonia
- Background
- Diagnostic Tests
- Vaccines and Drugs
* Polyomaviruses
- Background
- Diagnostic Tests
- Vaccines and Drugs
* Salmonellosis
- Background
- Diagnostic Tests
- Vaccines and Drugs
* Shigellosis
- Background
- Diagnostic Tests
- Vaccines and Drugs
* Streptococci
- Background
- Diagnostic Tests
- Vaccines and Drugs
- Group A Streptococci
- Group B Streptococci
Competing in the European Molecular Diagnostics Market: France, Germany, Italy, Spain, UK (From Slideshare) Page 7/18
8. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
* Toxoplasmosis
- Background
- Diagnostic Tests
- Vaccines and Drugs
* Tuberculosis
- Background
- Diagnostic Tests
- Microscopic Characteristics
- Cultural Characteristics
- Skin Tests
- MDRTB
- Vaccines and Drugs
* West Nile Virus
- Background
- Clinical Syndromes
- Diagnostic Tests
- Vaccines and Drugs
* Yersinia
- Background
- Diagnostic Tests
- Vaccines and Drugs
c. Antibiotic Susceptibility
2. Cancer Testing
a. Overview
b. Major Cancer Types
* Prostate
* Lung
* Colon and Rectum
* Breast
* Skin
* Uterine
* Leukemia
* Oral
c. Oncogenes
- Abl/abl-bcr
- AIB1
- BCL-2
- BRCA1
- CD44
- C-fos
- C-myb
- C-myc
- CYP17
- Erb-B
- HPC1
- N-myc
- P40
- P51
Competing in the European Molecular Diagnostics Market: France, Germany, Italy, Spain, UK (From Slideshare) Page 8/18
9. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
- P53
- PIK3CA
- PTI-1
- Ras
- Reg
- Sis
- Src
3. Genetic Diseases
a. Overview
b. Nucleic Acid Amplification
c. Chromosome Imaging
d. Genomics Technologies
e. Proteomics Technologies
f. Current Pharmacogenomic Tests
g. Future Pharmacogenomic Testing
h. Major Diseases
* Achondroplasia
* Autosomal Dominant Polycystic Kidney
Disease
* Cancer
* Cosmetogenomics
* Cystic Fibrosis
* Down's Syndrome
* Duchenne and Becker Muscular Dystrophy
* Factor V (Leiden)
* Factor IX Deficiency
* Fragile X Syndrome
* Heart Disease
* Hemochomatosis
* Hemophilia
* Huntington's Disease
* Maternal-Fetal Incompatibility
* Multiple Endocrine Neoplasia
* Phenylketonuria (PKU)
* Polycystic Kidney Disease (PKD)
* Prenatal Screening
* Retinitis Pigmentosa
* Retinoblastoma
* Sickle Cell Anemia
* Spinal Muscular Atrophy
* Vitamin B12 Metabolism
i. Social Issues and Concerns
4. Forensic Testing
a. Overview
b. Multilocus and Single Locus Probes
* Multilocus Probes
* Single Locus Probes
* PCR and RFLP
Competing in the European Molecular Diagnostics Market: France, Germany, Italy, Spain, UK (From Slideshare) Page 9/18
10. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
c. The FBI
d. DNA Profile Data Banks
* U.S.A.
* U.K.
e. Judicial Implementation
f. Major Crime Categories
g. Factors Contributing t - the DNA Probe
Market Expansion
* Technology Availability
* Use of Hair as Evidence
h. Wildlife Forensics
5. Paternity Testing/HLA Typing
6. Other Applications
a. Disease Susceptibility Testing
b. Cardiovascular Diseases
c. Diabetes
d. Alzheimer's Disease
e. Periodontal Disease
f. Plasma Purification
g. Organ Transplantation
h. Water Contamination
i. Other
H. Competing/complementing Technologies
1. Monoclonal Antibodies/Immunoassays
2. RNA Probes
3. Two-Dimensional Electrophoresis
4. Flow Cytometry
France
A. Executive Summary
B. Business Environment
C. Market Structure
D. Market Size, Growth And Major Suppliers'
Sales And Market Shares
Germany
A. Executive Summary
B. Business Environment
C. Market Structure
D. Market Size, Growth And Major Suppliers'
Sales And Market Shares
Italy
A. Executive Summary
B. Business Environment
C. Market Structure
D. Market Size, Growth And Major Suppliers'
Sales And Market Shares
Spain
A. Executive Summary
B. Business Environment
Competing in the European Molecular Diagnostics Market: France, Germany, Italy, Spain, UK (From Slideshare) Page 10/18
11. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
C. Market Structure
D. Market Size, Growth And Major Suppliers'
Sales And Market Shares
U.K.
A. Executive Summary
B. Business Environment
C. Market Structure
D. Market Size, Growth And Major Suppliers'
Sales And Market Shares
Major Product Development Opportunities
A. Instrumentation
B. Reagent Kits and Test Systems/panels
C. Computers, Software and Automation
D. Auxiliary Products
Design Criteria For Decentralized Testing Products
Alternative Market Penetration Strategies
A. Internal Development
B. Collaborative Arrangements
C. University Contracts
D. Distribution Strategies For Decentralized Testing
Markets
1. Marketing Approaches
2. Product Complexity
3. Customer Preference
4. Established Suppliers
5. Emerging Suppliers
6. Major Types Of Distributors
7. Market Segmentation
Potential Market Entry Barriers And Risks
A. Market Maturity
B. Cost Containment
C. Competition
D. Technological Edge And Limitations
E. Patent Protection
F. Regulatory Constraints
G. Decentralized Testing Market Challenges
Competitive Profiles
- Abbott
- Affymetrix
- Agilent
- Applied Gene Technologies
- Beckman Coulter/Danaher
- Becton Dickinson
- Biokit
- BioMerieux
- Bio-Rad
- Biotest
- Caliper
Competing in the European Molecular Diagnostics Market: France, Germany, Italy, Spain, UK (From Slideshare) Page 11/18
12. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
- Cepheid
- Decode
- Diadexus
- Eiken
- Enzo
- Exact Sciences
- Fujirebio
- Gen-Probe
- Hologic
- Illumina
- Innogenetics/Solvay
- Kreatech
- Li-Cor Biosciences
- Life Technologies
- Monogram Biosciences
- Myriad Genetics
- Nanogen/Elitech
- Novartis
- Nuvelo
- Orchid CellMark
- Ortho-Clinical Diagnostics
- Proteome Sciences
- Qiagen
- Roche
- Scienion
- Sequenom
- Shimadzu
- Siemens
- Sierra Molecular
- Takara Bio
- Tecan Group
Appendixes
Appendix I: Major Universities and Research
Centers
Developing Molecular Diagnostic
Technology
Appendix II: Glossary of Terms
Appendix III: Currency Exchange Rates
List of Tables
Major Companies Developing or Marketing AIDS Molecular
Diagnostic And Other Direct Identification Tests
Major Companies Developing or Marketing Adenovirus
Molecular Diagnostic And Other Direct
Identification Tests
Competing in the European Molecular Diagnostics Market: France, Germany, Italy, Spain, UK (From Slideshare) Page 12/18
13. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Major Companies Developing or Marketing Campylobacter
Molecular Diagnostic And Other Direct
Identification Tests
Major Companies Developing or Marketing Chlamydia
Molecular Diagnostic And Other Direct
Identification Tests
Major Companies Developing or Marketing CMV Molecular
Diagnostic And Other Direct Identification Tests
Major Companies Developing or Marketing EBV Molecular
Diagnostic And Other Direct Identification Tests
Major Companies Developing or Marketing Gonorrhea
Molecular Diagnostic And Other Direct
Identification Tests
Major Companies Developing or Marketing Hepatitis
Molecular Diagnostic And Other Direct
Identification Tests
Major Companies Developing or Marketing Herpes
Molecular Diagnostic And Other Direct
Identification Tests
Major Companies Developing or Marketing Legionella
Molecular Diagnostic And Other Direct
Identification Tests
Major Companies Developing or Marketing Lyme
Disease Molecular Diagnostic And Other Direct
Identification Tests
Major Companies Developing or Marketing Mycoplasma
Molecular Diagnostic And Other Direct
Identification Tests
Major Companies Developing or Marketing Papilloma
Virus Molecular Diagnostic And Other Direct
Identification Tests
Major Companies Developing or Marketing Pneumonia
Molecular Diagnostic And Other Direct
Identification Tests
Major Companies Developing or Marketing Salmonella
Molecular Diagnostic And Other Direct
Identification Tests
Major Companies Developing or Marketing Shigella
Molecular Diagnostic And Other Direct
Identification Tests
Major Companies Developing or Marketing Streptococci
Molecular Diagnostic And Other Direct
Identification Tests
Major Companies Developing or Marketing Toxoplasmosis
Molecular Diagnostic And Other Direct
Identification Tests
Major Companies Developing or Marketing Tuberculosis
Molecular Diagnostic And Other Direct
Competing in the European Molecular Diagnostics Market: France, Germany, Italy, Spain, UK (From Slideshare) Page 13/18
14. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Identification Tests
Oncogenes Potential Application in Cancer Diagnosis
Major Companies Developing or Marketing Cancer
Molecular Diagnostic Tests
Major Companies Developing or Marketing Molecular
Diagnostic Test For Genetic Diseases
Summary Table France, Molecular Diagnostic Test Volume
And Sales Forecast by Major Application
France, Laboratories Performing DNA Sequencing
By Market Segment
France, Molecular Diagnostics Market Potential
Laboratory Universe by Market Segment
France, Molecular Diagnostic Test Volume Forecast
By Major Application
France, Major Infectious Disease Molecular
Diagnostics Test Volume Forecast
France, Infectious Disease Screening
NAT Volume Forecast
France, Molecular Diagnostics Market Forecast
By Major Application
France, Infectious Disease Screening NAT Reagent
Market Forecast by Test
France, Molecular Diagnostics Market
By Major Supplier
France, HIV/Hepatitis NAT Market Reagent Sales
By Major Supplier
Summary Table Germany, Molecular Diagnostics Test Volume
And Sales Forecast by Major Application
Germany, Laboratories Performing
DNA Sequencing by Market Segment
Germany, Molecular Diagnostics Market
Potential Laboratory Universe by Market Segment
Germany, Molecular Diagnostics Test Volume Forecast
By Major Application
Germany, Major Infectious Disease Molecular
Diagnostics Test Volume Forecast
Germany, Infectious Disease Screening
NAT Volume Forecast
Germany, Molecular Diagnostics Market Forecast
By Major Application
Germany, Infectious Disease Screening
NAT Reagent Market Forecast by Test
Germany, Molecular Diagnostics
Market by Major Supplier
Germany, HIV/Hepatitis NAT Market Reagent
Sales by Major Supplier
Summary Table Italy, Molecular Diagnostics Test Volume
And Sales Forecast by Major Application
Competing in the European Molecular Diagnostics Market: France, Germany, Italy, Spain, UK (From Slideshare) Page 14/18
15. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Italy, Laboratories Performing
DNA Sequencing by Market Segment
Italy, Molecular Diagnostics Market Potential
Laboratory Universe by Market Segment
Italy, Molecular Diagnostics Test Volume Forecast
By Major Application
Italy, Major Infectious Disease Molecular
Diagnostics Test Volume Forecast
Italy, Infectious Disease Screening
NAT Volume Forecast
Italy, Molecular Diagnostics Market Forecast
By Major Application
Italy, Infectious Disease Screening
Nat Reagent Market Forecast by Test
Italy, Molecular Diagnostics Market
By Major Supplier
Italy, HIV/Hepatitis NAT Market
By Major Supplier
Summary Table Spain, Molecular Diagnostics Test Volume
And Sales Forecast by Major Application
Spain, Laboratories Performing
DNA Sequencing by Market Segment
Spain, Molecular Diagnostics Market, Potential
Laboratory Universe by Market Segment
Spain, Molecular Diagnostics Test Volume
Forecast by Major Application
Spain, Major Infectious Disease Molecular
Diagnostics Test Volume Forecast
Spain, Infectious Disease Screening
NAT Volume Forecast
Spain, Molecular Diagnostics Market Forecast
By Major Application
Spain, Infectious Disease Screening Nat
Reagent Market Forecast by Test
Spain, Molecular Diagnostics Market
By Major Supplier
Spain, HIV/Hepatitis NAT Market Reagent
Sales by Major Supplier
Summary Table U.K., Molecular Diagnostics Test Volume
And Sales Forecast by Major Application
U.K., Laboratories Performing
Dna Sequencing by Market Segment
U.K., Molecular Diagnostics Market Potential
Laboratory Universe by Market Segment
U.K., Molecular Diagnostics Test Volume Forecast
By Major Application
U.K., Major Infectious Disease Molecular
Diagnostics Test Volume Forecast
Competing in the European Molecular Diagnostics Market: France, Germany, Italy, Spain, UK (From Slideshare) Page 15/18
16. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
U.K., Infectious Disease Screening
NAT Volume Forecast
U.K., Molecular Diagnostics Market Forecast
By Major Application
U.K., Infectious Disease Screening NAT Reagent
Market Forecast by Test
U.K., Molecular Diagnostics Market by Major Supplier
Competing in the European Molecular Diagnostics Market: France, Germany, Italy, Spain, UK (From Slideshare) Page 16/18
17. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact
Order Information
Please verify that the product information is correct and select the format(s) you require.
Competing in the European Molecular Diagnostics Market: France, Germany, Italy, Spain, UK
Product Formats
Please select the product formats and the quantity you require.
Data Tables only--USD 12 800.00 Quantity: _____
Local PDF--USD 19 700.00 Quantity: _____
Global PDF--USD 43 300.00 Quantity: _____
Contact Information
Please enter all the information below in BLOCK CAPITALS
Title: Mr Mrs Dr Miss Ms Prof
First Name: _____________________________ Last Name: __________________________________
Email Address: __________________________________________________________________________
Job Title: __________________________________________________________________________
Organization: __________________________________________________________________________
Address: __________________________________________________________________________
City: __________________________________________________________________________
Postal / Zip Code: __________________________________________________________________________
Country: __________________________________________________________________________
Phone Number: __________________________________________________________________________
Fax Number: __________________________________________________________________________
Competing in the European Molecular Diagnostics Market: France, Germany, Italy, Spain, UK (From Slideshare) Page 17/18
18. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Payment Information
Please indicate the payment method, you would like to use by selecting the appropriate box.
Payment by credit card Card Number: ______________________________________________
Expiry Date __________ / _________
CVV Number _____________________
Card Type (ex: Visa, Amex…) _________________________________
Payment by wire transfer Crédit Mutuel
RIB : 10278 07314 00020257701 89
BIC : CMCIFR2A
IBAN : FR76 1027 8073 1400 0202 5770 189
Payment by check UBIQUICK SAS
16 rue Grenette – 69002 LYON, FRANCE
Customer signature:
Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
http://www.reportlinker.com/index/terms
Please fax this form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
Competing in the European Molecular Diagnostics Market: France, Germany, Italy, Spain, UK (From Slideshare) Page 18/18